Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ELOX | Common Stock | Purchase | $114K | +84.8K | +97.41% | $1.35 | 172K | May 13, 2021 | See footnote | F1, F2 |
transaction | ELOX | Common Stock | Purchase | $3.22M | +2.38M | +97.41% | $1.35 | 4.83M | May 13, 2021 | See footnote | F1, F3 |
Id | Content |
---|---|
F1 | Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. |
F2 | Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. |
F3 | Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. |